Compare · ALUR vs SYK
ALUR vs SYK
Side-by-side comparison of Allurion Technologies Inc. (ALUR) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALUR and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK carries a market cap of $112.48B.
- Over the past year, ALUR is down 97.7% and SYK is down 22.8% - SYK leads by 74.9 points.
- SYK has been more active in the news (7 items in the past 4 weeks vs 1 for ALUR).
- SYK has more recent analyst coverage (25 ratings vs 4 for ALUR).
- Company
- Allurion Technologies Inc.
- Stryker Corporation
- Price
- $0.68-5.00%
- $294.69+0.46%
- Market cap
- -
- $112.48B
- 1M return
- +0.00%
- +5.16%
- 1Y return
- -97.71%
- -22.78%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 1
- 7
- Recent ratings
- 4
- 25
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest ALUR
- SEC Form 25-NSE filed by Allurion Technologies Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Allurion Technologies Inc.
- Allurion Technologies Inc. filed SEC Form 8-K: Leadership Update
- SEC Form NT 10-Q filed by Allurion Technologies Inc.
- Allurion Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Amendment: SEC Form SCHEDULE 13D/A filed by Allurion Technologies Inc.
- Large owner Rtw Investments, Lp disposed of 392,766 shares (SEC Form 4)
- Allurion Technologies Inc. filed SEC Form 8-K: Leadership Update
- Allurion Technologies Inc. filed SEC Form 8-K: Leadership Update
- Allurion Technologies Inc. filed SEC Form 8-K: Leadership Update
Latest SYK
- Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal
- Stryker and CMR Surgical announce strategic alliance to advance robotic-assisted surgery
- Barclays initiated coverage on Stryker with a new price target
- SEC Form 8-K filed by Stryker Corporation
- Stryker announces leadership succession
- Stryker to announce third quarter 2026 financial results
- VP, Chief Financial Officer Wells Preston Wendell disposed of 109 shares, decreasing direct ownership by 3% to 3,661 units (SEC Form 4)
- VP, Chief Financial Officer Wells Preston Wendell disposed of 2,739 shares, decreasing direct ownership by 42% to 3,770 units (SEC Form 4)
- Stryker showcases Foot & Ankle innovation at AOFAS 2026 with Prophecy® Surgical Planning for Incompass™ and Hoffmann® LRF smartHEX™
- New insider Baculik Emily Kay claimed ownership of 1,554 shares (SEC Form 3)